Segmented Linear Mixed Model Analysis Reveals Association of the APOE ε4 Allele with Faster Rate of Alzheimer's Disease Dementia Progression

Manuscript Number: 

21-0434R1

Author(s): 
X. Richard Chen, Martin Sadowski, Yongzhao Shao

Disclosures

X. Richard Chen

  • Nothing to Disclose

Martin Sadowski

  • Consulting Fees:
    Consulting fees: Adept Field Solutions, PA USA; Biogen Inc, MA, USA; Decision Resource Group) MA, USA; Gerson Lehrman Group) NY, USA; Guidepoint Consulting, NY, USA; Noble Insights, Inc. NJ, USA
    Sponsors:
    The site principal investigator at New York University Grossman School of Medicine for Alzheimer’s Disease Neuroimaging Initiative (ADNI) 2 and 3 studies, which support is derived from NIA grant U01 AG024904 PI M Weiner
    Patents/Royalties
    U.S. Patent No. 9,364,449 unlicensed
    Grants
    • Agency: 
      Biogen Inc, MA - clinical trial site for AD drugs
      Dates: 
      2015-ongoing
    • Agency: 
      Eisai Co., Ltd - clinical trial site for AD drugs
      Dates: 
      2020-ongoing
    • Agency: 
      Novartis Pharma - clinical trial site for AD drugs
      Dates: 
      2016-ongoing
    • Agency: 
      Suven Life Sciences Ltd. - clinical trial site for AD drugs
      Dates: 
      2016-2021
    • Agency: 
      Merck Sharp & Dohme Corp.- clinical trial site for AD drugs
      Dates: 
      2014-2020
    • Agency: 
      Neurotrack Technologies Inc. - Industry Research Grant
      Dates: 
      2014-2019
    • Agency: 
      Janssen Research and Development- Industry Research Grant
      Dates: 
      2014-2019
    • Agency: 
      Eli Lilly & Company - clinical trial site for AD drugs
      Dates: 
      2021-ongoing

Yongzhao Shao

  • Nothing to Disclose